STK36 and metabolic syndrome: The Mito-Fu family and its archetype, a cytochrome c oxidase inhibitor designed by Collman and Fu, have been reported to improve the quality and dynamics of mitochondria in the liver to correct the early stage of metabolic syndrome (4).